Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Endocrinology
•
HIV & AIDS
What patient-specific factors would influence your decision to initiate semaglutide therapy in patients with HIV-associated lipohypertrophy?
Answer from: at Community Practice
I would consider it if the patient had diabetes. But there is not much data on this question.
Comments
at George Washington School Of Medicine
Is there any data?
13807
Sign in or Register to read more
25057
Related Questions
How do you use CD4% in clinical practice in management of patients living with HIV?
What are your top takeaways from ID Week 2024?
What steps do you recommend to ensure continued viral suppression and prevent drug resistance in an HIV patient on injectable cabotegravir and rilpivirine who misses their scheduled injection appointment by two weeks?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
Do you routinely prescribe GLP-1 receptor agonists to people living with HIV (PLH) with obesity?
How do you counsel HIV patients with an undetectable viral load on breastfeeding?
What is your approach to a positive PPD or IGRA in a patient with well-controlled HIV without significant TB risk factors?
Is there a role for routine LP in HIV patients with disseminated histoplasmosis even in the absence of CNS signs/symptoms?
How would you manage a patient with well controlled HIV on Biktarvy, who is interested in switching to injectable HAART but also has a history of a prior Hepatitis B Infection?
Is there any data?